F. H. Dexeus

1.5k total citations · 1 hit paper
14 papers, 1.1k citations indexed

About

F. H. Dexeus is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, F. H. Dexeus has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Neurology. Recurrent topics in F. H. Dexeus's work include Bladder and Urothelial Cancer Treatments (6 papers), Urinary and Genital Oncology Studies (5 papers) and Testicular diseases and treatments (3 papers). F. H. Dexeus is often cited by papers focused on Bladder and Urothelial Cancer Treatments (6 papers), Urinary and Genital Oncology Studies (5 papers) and Testicular diseases and treatments (3 papers). F. H. Dexeus collaborates with scholars based in United States and Spain. F. H. Dexeus's co-authors include Avishay Sella, C. Logothetis, R. J. Amato, Robert G. Kilbourn, Alberto G. Ayala, Laura Finn, Christopher J. Logothetis, Douglas E. Johnson, David A. Swanson and M. L. Samuels and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Hormone and Metabolic Research.

In The Last Decade

F. H. Dexeus

14 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

1990 463 citations C. Logothetis, F. H. Dexeus et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. H. Dexeus United States	11	840	359	295	181	94	14	1.1k
Kamal S. Pohar United States	21	779 0.9×	214 0.6×	197 0.7×	269 1.5×	70 0.7×	57	1.2k
Kevin A. David United States	16	317 0.4×	660 1.8×	109 0.4×	225 1.2×	75 0.8×	41	1.2k
D. Roychowdhury United States	11	1.5k 1.8×	799 2.2×	435 1.5×	367 2.0×	190 2.0×	17	2.1k
J.M. Giménez Bachs Spain	17	270 0.3×	111 0.3×	190 0.6×	382 2.1×	72 0.8×	77	823
Giovanni Casetta Italy	17	427 0.5×	154 0.4×	152 0.5×	345 1.9×	60 0.6×	50	887
R. R. Hall United Kingdom	14	427 0.5×	246 0.7×	288 1.0×	121 0.7×	47 0.5×	26	819
Tateki Yoshino Japan	14	257 0.3×	185 0.5×	458 1.6×	208 1.1×	49 0.5×	35	863
Peter J. Goebell Germany	19	932 1.1×	271 0.8×	314 1.1×	431 2.4×	37 0.4×	62	1.3k
Ilaria Lucca Switzerland	23	744 0.9×	456 1.3×	492 1.7×	258 1.4×	124 1.3×	70	1.4k
Fabiana Letizia Cecere Italy	14	238 0.3×	404 1.1×	385 1.3×	356 2.0×	33 0.4×	56	916

Countries citing papers authored by F. H. Dexeus

Since Specialization

Citations

This map shows the geographic impact of F. H. Dexeus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. H. Dexeus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. H. Dexeus more than expected).

Fields of papers citing papers by F. H. Dexeus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. H. Dexeus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. H. Dexeus. The network helps show where F. H. Dexeus may publish in the future.

Co-authorship network of co-authors of F. H. Dexeus

This figure shows the co-authorship network connecting the top 25 collaborators of F. H. Dexeus. A scholar is included among the top collaborators of F. H. Dexeus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. H. Dexeus. F. H. Dexeus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Vassilopoulou‐Sellin, Rena, et al.. (1992). Acute Thyroid Dysfunction (Thyroiditis) after Therapy with Interleukin-2. Hormone and Metabolic Research. 24(9). 434–438. 30 indexed citations

Logothetis, Christopher J., Elizabeth Hossan, Avishay Sella, F. H. Dexeus, & R. J. Amato. (1991). Fluorouracil and Recombinant Human Interferon Alfa-2a in the Treatment of Metastatic Chemotherapy-Refractory Urothelial Tumors. JNCI Journal of the National Cancer Institute. 83(4). 285–288. 52 indexed citations

Neidhart, James A., James Harris, J. J. Rinehart, et al.. (1991). Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases.. Journal of Clinical Oncology. 9(5). 832–836. 72 indexed citations

Sella, Avishay, et al.. (1991). Cisplatin Combination Chemotherapy for Elderly Patients with Urothelial Tumours. British Journal of Urology. 67(6). 603–607. 11 indexed citations

Logothetis, Christopher J., F. H. Dexeus, Avishay Sella, et al.. (1990). Escalated Therapy for Refractory Urothelial Tumors: Methotrexate- Vinblastine-Doxorubicin- Cisplatin Plus Unglycosylated Recombinant Human Granulocyte-macrophage Colony-Stimulating Factor. JNCI Journal of the National Cancer Institute. 82(8). 667–672. 86 indexed citations

Dexeus, F. H., et al.. (1990). Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 8(2). 325–329. 88 indexed citations

Logothetis, C., F. H. Dexeus, Laura Finn, et al.. (1990). A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.. Journal of Clinical Oncology. 8(6). 1050–1055. 463 indexed citations breakdown →

Logothetis, Christopher J., F. H. Dexeus, Clayton Chong, Avishay Sella, & Sheryl Ogden. (1990). The impact of chemotherapy on the survival of patients with metastatic urothelial tumors.. PubMed. 350. 107–14. 3 indexed citations

Logothetis, C., Douglas E. Johnson, Clayton Chong, et al.. (1988). Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update.. Journal of Clinical Oncology. 6(10). 1590–1596. 119 indexed citations

10.

Logothetis, Christopher J., David A. Swanson, F. H. Dexeus, et al.. (1987). Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.. Journal of Clinical Oncology. 5(6). 906–911. 59 indexed citations

11.

Dexeus, F. H., et al.. (1986). Phase II study of spirogermanium in metastatic prostate cancer.. PubMed. 70(9). 1129–30. 4 indexed citations

12.

Logothetis, Christopher J., M. L. Samuels, Debra E. Selig, & F. H. Dexeus. (1985). Update of cyclic chemotherapy in 100 patients (pts) with advanced nonseminomatous germ cell tumors (NSGCT). Proceedings of the American Association for Cancer Research. 26. 1 indexed citations

13.

Dexeus, F. H., Christopher J. Logothetis, M. L. Samuels, Elizabeth Hossan, & Andrew C. von Eschenbach. (1985). Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.. PubMed. 69(7-8). 885–6. 40 indexed citations

14.

Logothetis, C., M. L. Samuels, Debra E. Selig, et al.. (1985). Chemotherapy of extragonadal germ cell tumors.. Journal of Clinical Oncology. 3(3). 316–325. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact